Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus LOPRESSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus LOPRESSOR.
COREG CR vs LOPRESSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Category C
Category C
Beta-Blocker
Beta-Blocker